Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity

Neuroscience Letters

Volumn 440, Issue 2, 2008, Pages 97-102

  Imamura, Keiko ^a   Takeshima, Takao ^a   Nakaso, Kazuhiro ^a   Ito, Satoru ^a   Nakashima, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Astrocyte; Dopaminergic neuron; Parkinson's disease; Proteasome inhibitor; SH SY5Y

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LACTACYSTIN; MICROTUBULE ASSOCIATED PROTEIN 2; PRAMIPEXOLE; TYROSINE 3 MONOOXYGENASE;

ARTICLE; ASTROCYTE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; NERVE CELL; NEUROPROTECTION; PRIORITY JOURNAL;

ACETYLCYSTEINE; ANIMALS; ASTROCYTES; BENZOTHIAZOLES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MICROTUBULE-ASSOCIATED PROTEINS; NEURONS; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TYROSINE 3-MONOOXYGENASE;

EID: 45449092100     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.05.067     Document Type: Article

References (33)

1. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339 (1998) 1044-1053
2. Alam M., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136 (2002) 317-324
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
4. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47 (1996) S153-S160
5. Danzeisen R., Schwalenstoecker B., Gillardon F., Buerger E., Krzykalla V., Klinder K., Schild L., Hengerer B., Ludolph A.C., Dorner-Ciossek C., and Kussmaul L. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-l-propylamino-benzathiazole dihydrochloride]. J. Pharmacol. Exp. Ther. 316 (2006) 189-199
6. Gu M., Iravani M.M., Cooper J.M., King D., Jenner P., and Schapira A.H. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91 (2004) 1075-1081
7. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y., and Taniguchi T. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417 (2001) 59-67
8. Kitamura Y., Kosaka T., Kakimura J.I., Matsuoka Y., Kohno Y., Nomura Y., and Taniguchi T. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54 (1998) 1046-1054
9. Presgraves S.P., Borwege S., Millan M.J., and Joyce J.N. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp. Neurol. 190 (2004) 157-170
10. 2-induced PC12 cell death. Naunyn Schmiedebergs Arch. Pharmacol. 372 (2006) 257-266
11. Izumi Y., Sawada H., Yamamoto N., Kume T., Katsuki H., Shimohama S., and Akaike A. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur. J. Pharmacol. 557 (2007) 132-140
12. Sayeed I., Parvez S., Winkler-Stuck K., Seitz G., Trieu I., Wallesch C.W., Schonfeld P., and Siemen D. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J. 20 (2006) 556-558
13. McNaught K.S., Jackson T., JnoBaptiste R., Kapustin A., and Olanow C.W. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 66 (2006) S37-S49
14. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
15. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
16. McNaught K.S., and Olanow C.W. Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 60 (2006) 243-247
17. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., and Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23 (2003) 8955-8966
18. Lev N., Melamed E., and Offen D. Apoptosis and Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 245-250
19. Takeshima T., Shimoda K., Johnston J.M., and Commissiong J.W. Standardized methods to bioassay neurotrophic factors for dopaminergic neurons. J. Neurosci. Methods 67 (1996) 27-41
20. Lambert M.P., Stevens G., Sabo S., Barber K., Wang G., Wade W., Krafft G., Snyder S., Holzman T.F., and Klein W.L. Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells. J. Neurosci. Res. 39 (1994) 377-385
21. Nakaso K., Nakamura C., Sato H., Imamura K., Takeshima T., and Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem. Biophys. Res. Commun. 339 (2006) 915-922
22. Imamura K., Takeshima T., Kashiwaya Y., Nakaso K., and Nakashima K. d-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. J. Neurosci. Res. 84 (2006) 1376-1384
23. Springer J.E., Azbill R.D., and Carlson S.L. A rapid and sensitive assay for measuring mitochondrial metabolic activity in isolated neural tissue. Brain Res. Brain Res. Protoc. 2 (1998) 259-263
24. Du F., Li R., Huang Y., Li X., and Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 22 (2005) 2422-2430
25. Li X., Peng C., Li L., Ming M., Yang D., and Le W. Glial cell-derived neurotrophic factor protects against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation. J. Gerontol. A Biol. Sci. Med. Sci. 62 (2007) 943-950
26. Su Y.R., Wang J., Wu J.J., Chen Y., and Jiang Y.P. Overexpression of lentivirus-mediated glial cell line-derived neurotrophic factor in bone marrow stromal cells and its neuroprotection for the PC12 cells damaged by lactacystin. Neurosci. Bull. 23 (2007) 67-74
27. Tapley P., Lamballe F., and Barbacid M. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 7 (1992) 371-381
28. Li A., Guo H., Luo X., Sheng J., Yang S., Yin Y., Zhou J., and Zhou J. Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons. FASEB J. 20 (2006) 1263-1265
29. Ohta M., Mizuta I., Ohta K., Nishimura M., Mizuta E., Hayashi K., and Kuno S. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 272 (2000) 18-22
30. Poeggeler B., Rassoulpour A., Wu H.Q., Guidetti P., Roberts R.C., and Schwarcz R. Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-d-aspartate neurotoxicity. Neuroscience 148 (2007) 188-197
31. Han S.K., Mytilineou C., and Cohen G. l-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 66 (1996) 501-510
32. Le W.D., Jankovic J., Xie W., and Appel S.H. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J. Neural Transm. 107 (2000) 1165-1173
33. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Miyoshi K., and Ogawa N. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res. 1029 (2004) 120-123